Yale School of Medicine: Anti-Obesity Medication Semaglutide Could Benefit Millions of Americans With Obesity and Cardiovascular Disease
November 16, 2023
November 16, 2023
NEW HAVEN, Connecticut, Nov. 16 (TNSres) -- The Yale University School of Medicine issued the following news:
Semaglutide (brand name: Wegovy(R)) has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans people with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows.
The research was based on the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight o . . .
Semaglutide (brand name: Wegovy(R)) has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans people with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows.
The research was based on the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight o . . .